Detalles de la búsqueda
1.
PlGF blockade does not inhibit angiogenesis during primary tumor growth.
Cell
; 141(1): 166-77, 2010 Apr 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-20371352
2.
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
N Engl J Med
; 378(24): 2288-2301, 2018 Jun 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-29863955
3.
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1).
Proc Natl Acad Sci U S A
; 115(43): E10119-E10126, 2018 10 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-30297397
4.
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.
Nature
; 515(7528): 563-7, 2014 Nov 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-25428504
5.
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
Lancet Oncol
; 20(7): 924-937, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31122901
6.
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Lancet
; 389(10066): 255-265, 2017 01 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-27979383
7.
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
Lancet
; 387(10030): 1837-46, 2016 Apr 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-26970723
8.
Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment.
Proc Natl Acad Sci U S A
; 110(15): 6079-84, 2013 Apr 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-23530240
9.
Phenotypical differences in connective tissue cells emerging from microvascular pericytes in response to overexpression of PDGF-B and TGF-ß1 in normal skin in vivo.
Am J Pathol
; 182(6): 2132-46, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23570836
10.
Transcriptional induction of salt-inducible kinase 1 by transforming growth factor ß leads to negative regulation of type I receptor signaling in cooperation with the Smurf2 ubiquitin ligase.
J Biol Chem
; 287(16): 12867-78, 2012 Apr 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-22378783
11.
Development of a robust flow cytometry-based pharmacodynamic assay to detect phospho-protein signals for phosphatidylinositol 3-kinase inhibitors in multiple myeloma.
J Transl Med
; 11: 76, 2013 Mar 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-23522020
12.
Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors.
J Pathol
; 227(4): 404-16, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22611017
13.
Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes.
Proc Natl Acad Sci U S A
; 107(50): 21248-55, 2010 Dec 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-21081700
14.
G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models.
Proc Natl Acad Sci U S A
; 106(16): 6742-7, 2009 Apr 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-19346489
15.
Case report: A persistently expanded T cell response in an exceptional responder to radiation and atezolizumab for metastatic non-small cell lung cancer.
Front Immunol
; 13: 961105, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36159875
16.
C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients.
PLoS One
; 16(2): e0246486, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33534859
17.
Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity.
Nat Cancer
; 2(1): 18-33, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35121890
18.
Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade.
J Immunother Cancer
; 9(4)2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33827905
19.
Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung Cancer.
Clin Lung Cancer
; 21(5): 455-463.e4, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32586767
20.
Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy.
Sci Transl Med
; 12(534)2020 03 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32161104